Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice.

This prospective study collected quality of life (QoL) and pain data during cabazitaxel treatment in patients with advanced metastatic or castration-resistant prostate cancer (mCRPC).

Functional Assessment of Cancer Therapy-Prostate (QoL) and Brief Pain Inventory-Short Form (pain) questionnaires were collected over 6 months.

In 61 patients with mCRPC (median age, 72 years) from 22 centers, metastatic sites were bones (97%), lymph nodes (36%), and visceral (20%); 25% received cabazitaxel in the second line, 29% in the third line, and 46% in the fourth line or beyond. All had been previously treated with docetaxel, except one with paclitaxel, and 75% also with abiraterone, enzalutamide, or both. The median cabazitaxel duration was 3.4 months. Forty-nine patients were evaluable for QoL and 44 for pain. QoL was improved in 37%, maintained in 35%, and deteriorated in 37%. In 27%, pain decreased ≥ 1 level and remained stable in 52%. A total of 34% lowered analgesic drug level. Prostate-specific antigen response ≥ 50% was observed in 11 (32.6%) patients, of whom 7 improved QoL and 1 was stable. At 6 months, 83.6% survived (95% confidence interval, 71.7%-90.8%). A total of 46% had ≥ 1 grade ≥ 3 adverse events, mainly anemia and neutropenia.

Although cabazitaxel was given as the third line and beyond for three-quarters of patients, over one-third had improved QoL and/or decreased pain during treatment.

Clinical genitourinary cancer. 2020 Mar 06 [Epub ahead of print]

Florence Joly, Stéphane Oudard, Karim Fizazi, Florence Tubach, Jérémy Jove, Clémentine Lacueille, Stéphanie Lamarque, Estelle Guiard, Aurélie Balestra, Cécile Droz-Perroteau, Annie Fourrier-Reglat, Magali Rouyer, Nicholas Moore

Medical Oncology Department, Centre François Baclesse, CHU Côte de Nacre, Caen, France., Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France., Medical Oncology Department, Institut Gustave Roussy, Villejuif, France., Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique Centre de Pharmacoépidémiologie (Cephepi), Paris, France., Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France., Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France; Inserm CIC1401 & U1219, Bordeaux, France., Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France; Inserm CIC1401 & U1219, Bordeaux, France. Electronic address: .